The BalancedInvestor Club

NTRP Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)$-2.280.0% YoY
Profit margin0.0%CONSUMER CYCLICAL
Market cap$37.3MMicro cap

Wall Street coverage

$7.83median target· current $2.59 (+202.3%)2 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
—
PEG ratio
—
P/B
6.34
P/S (TTM)
17.12
EV/EBITDA
-0.57

Profitability & growth

ROE (TTM)
-681.0%
Operating margin
-257.0%
Revenue growth YoY
1508.0%
Dividend yield
—
Beta
3.34
Last earnings
Dec 31, 2025 · Estimate $-0.16 · Reported $-0.37
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About NextTrip Inc

Neurotrope, Inc., a biopharmaceutical company, is focused on developing a product platform for the treatment of Alzheimer's disease. The company is headquartered in New York, New York.

Classification

Sector
Consumer Cyclical
Industry
Travel Services
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
3900 PASEO DEL SOL, SANTA FE, NM
Fiscal year end
December
Latest quarter
Dec 31, 2025
Market cap$37.3M
Shares outstanding$13.6M
52W high$5.20
52W low$1.72

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer